[ad_1]
The Ministry of Health announced that it was extending the treatment offered to patients with age-related macular degeneration by offering antigenic drug and optical coherence tomography. According to the record, both incorporations are important for the early detection and treatment of previously confirmed cases, stabilizing the course of the disease. Macular degeneration reaches the central part of the retina and causes progressive loss of central vision.
The two new procedures should be addressed to patients from the age of 60, in accordance with the clinical protocol and therapeutic principles of age-related macular degeneration. The antigenic drug is injectable and can be administered in one or both eyes, with a minimum interval of 15 days between one eye and the other. Optical coherence tomography is a non-invasive diagnostic test for the disease of both eyes.
Disease
Age-related macular degeneration is a progressive disease that affects the central region of the retina, where images are formed, invariably causing vision loss. central The main risk factor is age. The disease can be clbadified as dry, responsible in most cases (85% to 90%) or humid (10% to 15%).
Edition: Juliana Andrade
Source link
